Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

New and experimental hepatitis C treatment news

Show

From To
UNITAID can address HCV/HIV co-infection

In the first days of March, the governing body of UNITAID, the organisation financed mainly through a levy on air tickets, will decide on a new 4-year strategy. We believe UNITAID's new strategy should also include tackling a prevalent and serious, but curable, HIV co-morbidity: hepatitis C virus (HCV) infection.

Published
23 February 2013
From
The Lancet
Regulators Await Gilead's Hep C Candidate

Gilead Sciences’ (GILD) sofosbuvir has passed all its preliminary examinations, and now is looking like a good bet for regulatory submissions in the coming months.

Published
22 February 2013
From
Seeking Alpha
Study may help design better DAA drug cocktails to treat HCV

The new study documents HCV kinetic modeling during treatment both in patients and in cell culture that provides insight into the modes of action of daclatasvir. In addition, the study suggests a more accurate estimate of HCV clearance from circulation.

Published
20 February 2013
From
News Medical
Gilead's Sofosbuvir for Hepatitis C Meets Primary Endpoint in Fourth Pivotal Phase 3 Study

Initial Regulatory Filings Planned for Q2 2013. Gilead Sciences (Nasdaq:GILD) today announced topline results from the Phase 3 FUSION study evaluating 12- and 16-week courses of therapy with the once-daily nucleotide sofosbuvir plus ribavirin (RBV) in treatment-experienced patients with genotype 2 or 3 chronic hepatitis C virus (HCV) infection who failed prior treatment.

Published
19 February 2013
From
Gilead press release
HCV polymerase inhibitor mericitabine boosts interferon/ribavirin cure rate

A 24-week response-guided triple regimen consisting of Roche's NS5B polymerase inhibitor mericitabine plus pegylated interferon and ribavirin produced a greater likelihood of sustained viral suppression than a 48-week course of pegylated interferon/ribavirin alone, according to a report in the January 28, 2013, online advance edition of Hepatology.

Published
13 February 2013
From
HIVandHepatitis.com
Copy of HCV polymerase inhibitor mericitabine boosts interferon/ribavirin cure rate

A 24-week response-guided triple regimen consisting of Roche's NS5B polymerase inhibitor mericitabine plus pegylated interferon and ribavirin produced a greater likelihood of sustained viral suppression than a 48-week course of pegylated interferon/ribavirin alone, according to a report in the January 28, 2013, online advance edition of Hepatology.

Published
13 February 2013
From
HIVandHepatitis.com
FISSION Study Should Support Regulatory Approval For Gilead's Hepatitis C Drug

On Monday, Gilead announced positive top‐line results from two Phase III studies (FISSION and NEUTRINO) that involve the use of sofosbuvir in combination with other agents for use in treatment‐naïve patients infected with the Hepatitis C virus (HCV).

Published
07 February 2013
From
Seeking Alpha
Idenix to Discontinue Development of Two Hepatitis C Treatments

Idenix Pharmaceuticals today announced the Company has elected not to continue its clinical development program for IDX184, a nucleotide polymerase inhibitor in phase IIb testing for the treatment of hepatitis C virus (HCV) infection, or to continue its development of IDX19368, an HCV nucleotide polymerase inhibitor for which the Company had previously filed an IND but had not initiated patient dosing.

Published
05 February 2013
From
Idenix press release
Gilead Announces Sustained Virologic Response Rates from Two Phase 3 Studies of Sofosbuvir for Hepatitis C

Gilead Sciences today announced topline results from two Phase 3 studies, FISSION and NEUTRINO, evaluating a 12-week course of the once-daily nucleotide sofosbuvir in combination with ribavirin (FISSION) and in combination with ribavirin and pegylated interferon (NEUTRINO) among treatment-naïve patients with chronic hepatitis C virus (HCV) infection.

Published
04 February 2013
From
Gilead press release
Vertex hepatitis C drug revenues plummet

Vertex Pharmaceuticals (Nasdaq: VRTX) saw sales of its hepatitis C drug, Incivek, drop off precipitously in the fourth quarter, year over year. The fast decline in Incivek sales, less than two years after its U.S. Food and Drug Administration approval.

Published
30 January 2013
From
Boston Business Journal (blog)

Filter by country